Literature DB >> 7691913

Classification of positive inotropic agents.

A M Feldman1.   

Abstract

Although there is increasing recognition that all inotropic agents are not alike, they continue to be viewed in the generic sense because of the lack of a classification system. Analogous to the classification system proposed for the antiarrhythmic agents over 20 years ago, a classification system is proposed that categorizes inotropic agents according to their mechanisms of action. Agents are classified as those that augment contractility by increasing intracellular levels of cyclic adenosine monophosphate (class I); affect ion channels or pumps (class II); modulate intracellular calcium regulation (class III), and augment contractility through multiple pathways (class IV). This classification system does not suggest that some classes of inotropic agents might be more effective than others nor does it imply that potential beneficial effects are shared by all members of each class of drugs. However, it provides a framework for better understanding of the potential benefits and limitations of the traditional inotropic agents as well as the increasing number of new investigational drugs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7691913     DOI: 10.1016/0735-1097(93)90441-3

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  6 in total

Review 1.  Novel drugs and current therapeutic approaches in the treatment of heart failure.

Authors:  V V Bonarjee; K Dickstein
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

Review 2.  Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.

Authors:  L Lehtonen
Journal:  Curr Cardiol Rep       Date:  2000-05       Impact factor: 2.931

3.  Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial.

Authors:  J Lubsen; H Just; A C Hjalmarsson; D La Framboise; W J Remme; J Heinrich-Nols; J M Dumont; P Seed
Journal:  Heart       Date:  1996-09       Impact factor: 5.994

Review 4.  Levosimendan: a calcium-sensitizing agent for the treatment of patients with decompensated heart failure.

Authors:  Lasse Lehtonen
Journal:  Curr Heart Fail Rep       Date:  2004-09

Review 5.  Pharmacokinetics and pharmacodynamics of intravenous inotropic agents.

Authors:  Lasse A Lehtonen; Saila Antila; Pertti J Pentikäinen
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  New arylsparteine derivatives as positive inotropic drugs.

Authors:  Vito Boido; Marcella Ercoli; Michele Tonelli; Federica Novelli; Bruno Tasso; Fabio Sparatore; Elena Cichero; Paola Fossa; Paola Dorigo; Guglielmina Froldi
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.